tailieunhanh - Báo cáo y học: "Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis. | Available online http content 1 2 5 R117 Research Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa activated in patients with severe sepsis Pierre-Franọois Laterre1 William L Macias2 Jonathan Janes3 Mark D Williams2 David R Nelson2 Amand RJ Girbes4 Jean-Franọois Dhainaut5 and Edward Abraham6 1st Luc University Hospital Avenue Hippocrate 10 1200 Brussels Belgium 2Lilly Research Laboratories Eli Lilly and Company Indianapolis IN 46285 USA 3Eli Lilly Erl Wood Manor Windlesham Surrey GU20 6PH UK 4Department of Intensive Care VU University Medical Center De Boelelaan 1105 1081 HVAmsterdam The Netherlands 5Paris Descartes University rue de l Ecole de Médecine 75270 Paris Cedex 06 Paris France 6University of Alabama at Birmingham School of Medicine 1530-3rd Avenue South FOT 1 203 Birmingham AL 35294 USA Corresponding author Pierre-Franọois Laterre laterre@ Received 14 Apr 2008 Revisions requested 30 May 2008 Revisions received 16 Jul 2008 Accepted 11 Sep 2008 Published 11 Sep 2008 Critical Care 2008 12 R117 doi cc7011 This article is online at http content 12 5 R117 2008 Laterre et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction We performed a study to determine whether an enrollment sequence effect noted in the PROWESS recombinant human activated Protein C Worldwide Evaluation in Severe Sepsis trial exists in the ADDRESS Administration of Drotrecogin Alfa Activated DrotAA in Early Stage Severe Sepsis trial. Methods We evaluated prospectively defined subgroups from two large phase 3 clinical trials ADDRESS which included 516 sites in 34 countries and PROWESS which included 164 sites